Is heart failure with mid range ejection fraction (HFmrEF) a distinct clinical entity or an overlap group?. (December 2018)

• Record Type: Journal Article
• Authors: Webb, Jessica; Draper, Jane; Fovargue, Lauren; Sieniewicz, Ben; Gould, Justin; Claridge, Simon; Barton, Carys; Smith, Silapiya; Tondel, Kristin; Rajani, Ronak; Kapetanakis, Stamatis; Rinaldi, Christopher A.; McDonagh, Theresa A.; Razavi, Reza; Carr-White, Gerald
• Is Part Of: IJC heart & vasculature. Volume 21(2018)
• Page Start: 1
• Page End: 6
• Publication Date: 2018-12
• Subjects: HFrEF, Heart Failure with reduced Ejection Fraction -- HFmrEF, Heart Failure with mid range Ejection Fraction -- HFpEF, Heart Failure with preserved Ejection Fraction -- NTproBNP, N terminal pro-B-type natriuretic peptide -- Transition; Cardiovascular system -- Diseases -- Periodicals; Cardiovascular system -- Pathophysiology -- Periodicals; 616.1005
• DOI: 10.1016/j.ijcha.2018.06.001
• Languages: English
• ISSNs: 2352-9067

Abstract

Abstract: Background: The new category of heart failure (HF), Heart Failure with mid range Ejection Fraction (HFmrEF) has recently been proposed with recent publications reporting that HFmrEF represents a transitional phase. The aim of this study was to determine the prevalence and clinical characteristics of patients with HFmrEF and to establish what proportion of patients transitioned to other types of HF, and how this affected clinical outcomes. Methods and results: Patients were diagnosed with HF according to the 2016 ESC guidelines. Clinical outcomes and variables were recorded for all consecutive in-patients referred to the heart failure service. In total, 677 patients with new HF were identified; 25.6% with HFpEF, 21% with HFmrEF and 53.5% with HFrEF. While clinical characteristics and prognostic factors of HFmrEF were intermediate between HFrEF and HFpEF, HFmrEF patients had the best outcome, with higher mortality in the HFrEF population (p 0.02) and higher HF rehospitalisation rates in the HFpEF population ( p < 0.01). 38.7% of the HFmrEF patients transitioned (56.4% to HFpEF and 43.6% to HFrEF) with fewest deaths in the patients that transitioned to HFpEF (p 0.04), and fewest HF readmissions in the patients that remained as HFmrEF (<0.01) Conclusion: HFmrEF patients had the best outcomes, compared to high rates of mortality seen in patients with HFrEF and high rates of HF readmissions seen in patients with HFpEF. Only 1/3 of HFmrEF patients transitioned during follow up, with the lowest mortality seen in patients transitioning to HFpEF.